RQ Bio
Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients
$115MSeries A
Role not disclosedWM
Wellington Management
Activity from announced rounds
Activity in this selectionSeries A
Wellington Management is an investment manager with a private-investing platform spanning venture capital, growth and private debt, informed by its public-market research.
Its equity strategies include early-stage venture, private biotech, climate growth and late-stage growth. These teams address different development needs, from scientific breakthroughs and medical demand to scaling industrial systems and preparing for public markets.
A Value Creation Team connects portfolio companies with Wellington’s public- and private-market specialists from seed through IPO. The wider platform also provides growth lending, giving some businesses a debt-financing route alongside equity capital.
Sources
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $327.5M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionKorsana Biosciences
Develops therapies for neurodegenerative diseases.
$175MSeries A
Role not disclosedCaldera Therapeutics
Develops bispecific antibody CLD-423 for inflammatory bowel disease
$37.5MSeries A1
Role not disclosed